Εμφάνιση απλής εγγραφής

dc.creatorLivanou E., Rouka E., Sinis S., Dimeas I., Pantazopoulos I., Papagiannis D., Malli F., Kotsiou O., Gourgoulianis K.I.en
dc.date.accessioned2023-01-31T08:55:20Z
dc.date.available2023-01-31T08:55:20Z
dc.date.issued2022
dc.identifier10.3390/jpm12040640
dc.identifier.issn20754426
dc.identifier.urihttp://hdl.handle.net/11615/75975
dc.description.abstractBackground: SARS-CoV-2 vaccines have shown high efficacy in protecting against COVID-19, although the determinants of vaccine effectiveness and breakthrough rates are yet to be determined. We aimed at investigating several factors affecting the SARS-CoV-2 IgG Spike (S) antibody responses on admission and clinical outcomes of COVID-19 disease in fully vaccinated, hospitalized patients. Methods: 102 subjects were enrolled in the study. Blood serum samples were collected from each patient upon admission for the semiquantitative determination of the SARS-CoV-2 IgG S levels with lateral flow assays. Factors influencing vaccine responses were documented. Results: 27 subjects had a negative antibody test upon hospital admission. Out of the 102 patients admitted to the hospital, 88 were discharged and 14 died. Both the absence of anti-S SARS-CoV-2 antibodies and poor clinical outcomes of COVID-19 disease were associated with older age, lower Ct values, and a shorter period between symptom onset and hospital admission. Ct values and time between symptom onset and hospitalization were independently associated with SARS-CoV-2 IgG S responses upon admission. The PaO2/FiO2 ratio was identified as an independent predictor of in-hospital mortality. Conclusions: Host-and disease-associated factors can predict SARS-CoV-2 IgG S responses and mortality in hospitalized patients with breakthrough SARS-CoV-2 Infection. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.language.isoenen
dc.sourceJournal of Personalized Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85129194382&doi=10.3390%2fjpm12040640&partnerID=40&md5=827da11ff3d2eb533faf71080fcded2f
dc.subjectalanine aminotransferaseen
dc.subjectaspartate aminotransferaseen
dc.subjectastrazeneca covid19 vaccineen
dc.subjectC reactive proteinen
dc.subjectcorticosteroiden
dc.subjectcovid19 vaccine biontech pfizeren
dc.subjectcreatine kinaseen
dc.subjectcreatinineen
dc.subjectelasomeranen
dc.subjectferritinen
dc.subjectlactate dehydrogenaseen
dc.subjectprobiotic agenten
dc.subjectSARS-CoV-2 antibodyen
dc.subjecttozinameranen
dc.subjectureaen
dc.subjectvaxzevriaen
dc.subjectageden
dc.subjectantibody responseen
dc.subjectArticleen
dc.subjectbody massen
dc.subjectcoronavirus disease 2019en
dc.subjectcycle threshold valueen
dc.subjectfemaleen
dc.subjectFisher exact testen
dc.subjectHorowitz indexen
dc.subjecthospitalizationen
dc.subjecthumanen
dc.subjectKolmogorov Smirnov testen
dc.subjectlateral flow immunochromatographyen
dc.subjectlogistic regression analysisen
dc.subjectlymphocyte counten
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectplatelet counten
dc.subjectreal time reverse transcription polymerase chain reactionen
dc.subjectsoftwareen
dc.subjectMDPIen
dc.titlePredictors of SARS-CoV-2 IgG Spike Antibody Responses on Admission and Clinical Outcomes of COVID-19 Disease in Fully Vaccinated Inpatients: The CoVax Studyen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής